Inventor
GOODRICH RAYMOND P
US19 patents
⚠️ This page may combine multiple inventors who share the name “GOODRICH RAYMOND P”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
CARIDIANBCT BIOTECHNOLOGIES LLC
6 patentsUS8016736B2Sep 13, 2011
Methods for washing a red blood cell component and for removing prions therefrom
CARIDIANBCT BIOTECHNOLOGIES LLC7 citations82
US7901673B2Mar 8, 2011
Induction of and maintenance of nucleic acid damage in pathogens using riboflavin and light
CARIDIANBCT BIOTECHNOLOGIES LLC5 citations59
US8044051B2Oct 25, 2011
Methods and compositions for the production of high concentration alloxazine solutions
CARIDIANBCT BIOTECHNOLOGIES LLC0 citations50
US8017110B1Sep 13, 2011
Induction of and maintenance of nucleic acid damage in pathogens using riboflavin and light
CARIDIANBCT BIOTECHNOLOGIES LLC1 citations49
US7892535B2Feb 22, 2011
Preventing transfusion related complications in a recipient of a blood transfusion
CARIDIANBCT BIOTECHNOLOGIES LLC0 citations48
US7985588B2Jul 26, 2011
Induction of and maintenance of nucleic acid damage in pathogens using riboflavin and light
CARIDIANBCT BIOTECHNOLOGIES LLC0 citations47
GAMBRO INC
5 patentsUS6280622B1Aug 28, 2001
System for using ligands in particle separation
GAMBRO INC55 citations95
US6843961B2Jan 18, 2005
Reduction of contaminants in blood and blood products using photosensitizers and peak wavelengths of light
GAMBRO INC46 citations89
US7186543B1Mar 6, 2007
Preparation of vaccines using a photosensitizer and light
GAMBRO INC7 citations73
US7049110B2May 23, 2006
Inactivation of West Nile virus and malaria using photosensitizers
GAMBRO INC7 citations69
US7183045B2Feb 27, 2007
Removal of adenine during a pathogen reduction process in whole blood or red blood cell by dilution
GAMBRO INC3 citations56
COBE LAB
2 patentsCARIDIANBCT BIOTECHNOLOGIES LL
2 patentsUS7648699B2Jan 19, 2010
Preventing transfusion related complications in a recipient of a blood transfusion
CARIDIANBCT BIOTECHNOLOGIES LL32 citations89
US7498156B2Mar 3, 2009
Use of visible light at wavelengths of 500 to 550 nm to reduce the number of pathogens in blood and blood components
CARIDIANBCT BIOTECHNOLOGIES LL25 citations89